Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 539-544

  Li, Yu Hong ^a   Wang, Feng Hua ^a   Jiang, Wen Qi ^a   Xiang, Xiao Juan ^a   Deng, Yan Ming ^b   Hu, Guo Qing ^c   Xu, De Ming ^d   Chen, Yan ^e   Lin, Qing ^f   He, You Jian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Central Hospital of Guangdong Provincial Agricultural Reclamation   (China)

^e SHANTOU CENTRAL HOSPITAL   (China)

^f Shunde TCM integrated Hospital   (China)

Author keywords

Capecitabine; Cisplatin; First line chemotherapy; Nasopharyngeal carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CISPLATIN; CREATININE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS;

EID: 45849122142     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0641-2     Document Type: Article

References (23)

1. Chan AT, Teo PM, Johnson PJ (2002) Nasopharyngeal carcinoma. Ann Oncol 13:1007-1015
2. Au E, Ang PT (1994) A phase II trail of 5-fluorouracial and cisplatin in recurrent and metastatic nasopharyngeal carcinoma. Ann Oncol 5:87-89
3. He YJ, Huang HQ (1994) Pilot study on combination of HDCF, 5-Fu and DDP treating advanced NPC (Chinese). Ai Zheng 13:236-239
4. Yu GS, He YJ, Hu YH (2001) Pilot study on biweekly regimen of cisplatin and 5-FU/LV treating NPC (Chinese). Ai Zheng 20:873-875
5. Yeo W, Leung TW, Leung SF, Teo PM, Chan AT, Lee WY, Johnson PJ (1996) Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 38:466-470
6. Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, Kwok CH, Chiu CY, Au SK, Foo W, Law CK, Tse KC (2002) Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 13:1252-1258
7. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK, Chua EJ (1999) Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10:235-237
8. Chua DT, Sham JS, Au GK (2005) A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 41:589-595
9. Ma BB, Chan AT (2005) Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 103:22-31
10. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generate 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281
11. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
12. Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, Kwon JH, Kim TY, Heo DS, Bang YJ, Kim NK (2004) Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluoroeracil/leucovorin chemotherapy. Jpn J Clin Oncol 34:400-404
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493
15. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
16. Chua DT, Sham JS, Au GK (2003) A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 39:361-366
17. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14:1115-1120
18. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893-1898
19. Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G (2003) Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 14:1576-1586
20. Kim JG, Sohn SK, Kim DH, Baek JH, Jeon SB, Chae YS, Lee KB, Park JS, Sohn JH, Kim JC, Park IK (2005) Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 93:1117-1121
21. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E (2000) Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 18:1324-1330
22. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292
23. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:4097-4106